DexCom — Apr 30, 2026 release

“We will work to build on this momentum throughout 2026 and look forward to highlighting Dexcom’s long-term growth opportunity at our Investor Day in the coming weeks.” 2026 Annual Guidance Dexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, and reiterating guidance for Revenue and Non-GAAP Gross Profit Margin at the following levels: • Revenue of $5.16 - $5.25 billion (approximately 11-13% growth) • Non-GAAP Gross Profit Margin of approximately 63-64% • Non-GAAP Operating Margin of approximately 23-23.5% • Adjusted EBITDA Margin of approximately 31-31.5% First Quarter 2026 Financial Results Revenue: In the first quarter of 2026, worldwide revenue grew 15% to $1.192 billion on a reported basis, up from $1.036 billion in the first quarter of 2025. Gross Profit: GAAP gross profit totaled $750.3 million or 62.9% of revenue for the first quarter of 2026, compared to $589.0 million or 56.9% of revenue in the first quarter of 2025. Non-GAAP gross profit* totaled $757.4 million or 63.5% of reported revenue for the first quarter of 2026, compared to $596.2 million or 57.5% of reported revenue in the first quarter of 2025. Operating Income: GAAP operating income for the first quarter of 2026 was $255.3 million or 21.4% of revenue, compared to GAAP operating income of $133.7 million or 12.9% of revenue for the first quarter of 2025. Non-GAAP operating income* for the first quarter of 2026 was $264.4 million or 22.2% of reported revenue, compared to non-GAAP operating income of $143.1 million or 13.8% of reported revenue for the first quarter of 2025. 1 First quarter 2026 organic revenue was $1.165 billion and excludes $26.6 million of foreign exchange impact. Net Income and Diluted Net Incom